89SrCl2在治疗乳腺癌骨转移中的临床疗效

目的 评价⁸⁹SrCl₂治疗乳腺癌骨转移的临床疗效,及其血液学毒副作用。方法 51例患者接受⁸⁹SrCl₂治疗,静脉注射剂量为2.22 MBq/kg体重,观察治疗前后止痛效果,病灶变化和外周血细胞变化。结果 患者疼痛完全缓解率为37.7%(17/45),总缓解率为84.4%。病灶治疗有效率为62.7%(32/51)。治疗后1个月白细胞和血小板减少者分别为76.5%和62.7%。3个月后大多数患者经治疗血象恢复到正常。结论 ⁸⁹SrCl₂可安全、有效地治疗乳腺癌骨转移患者的疼痛,并对其生活质量有所改善。

Clinical effect of 89SrCl2 in the treatment of breast cancer patients with bone metastasis

Objective To evaluate the clinical effect of ⁸⁹SrCl₂ as a palliative therapy for breast cancer patients with bone metastasis, and to observe the hematological toxicity induced by ⁸⁹SrCl₂ treatment. Methods ⁸⁹SrCl₂ dosage was 2.22 MBq/kg each time by intravenous for 51 patients. The analog scale, the cancer size and the hematological toxicity of ⁸⁹SrCl₂ treatment were observed. Results 17 patients (37.7%) among 45 patients became free of pain. The total pain relief rate was 84.4%.The response rate of metastatic sites was 62.7%. Approximately 76.5% of patients experienced neutropenia one month after theatment,whereas 62.7% of patients experienced thrombocytopenia. But the most of the patients could recover to the normal level 3 months after treatment. Conclusions ⁸⁹SrCl₂ is an effective and safe way for the pain relief and the life quality improvement in breast cancer patients with bone metastasis.